Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models.

Zuccolotto G, Fracasso G, Merlo A, Montagner IM, Rondina M, Bobisse S, Figini M, Cingarlini S, Colombatti M, Zanovello P, Rosato A.

PLoS One. 2014 Oct 3;9(10):e109427. doi: 10.1371/journal.pone.0109427. eCollection 2014.

2.

Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy.

Ma Q, Safar M, Holmes E, Wang Y, Boynton AL, Junghans RP.

Prostate. 2004 Sep 15;61(1):12-25.

PMID:
15287090
3.

Targeted elimination of prostate cancer by genetically directed human T lymphocytes.

Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, Brentjens R, Zhong XS, Stephan M, Stefanski J, Lyddane C, Osborne JR, Buchanan IM, Hall SJ, Heston WD, Rivière I, Larson SM, Koutcher JA, Sadelain M.

Cancer Res. 2005 Oct 1;65(19):9080-8.

4.

T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression.

Santoro SP, Kim S, Motz GT, Alatzoglou D, Li C, Irving M, Powell DJ Jr, Coukos G.

Cancer Immunol Res. 2015 Jan;3(1):68-84. doi: 10.1158/2326-6066.CIR-14-0192. Epub 2014 Oct 30.

5.

Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.

Fortmüller K, Alt K, Gierschner D, Wolf P, Baum V, Freudenberg N, Wetterauer U, Elsässer-Beile U, Bühler P.

Prostate. 2011 May;71(6):588-96. doi: 10.1002/pros.21274. Epub 2010 Oct 13.

PMID:
20945402
6.

Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.

Ma Q, Gomes EM, Lo AS, Junghans RP.

Prostate. 2014 Feb;74(3):286-96. doi: 10.1002/pros.22749.

PMID:
24174378
7.

The therapeutic potential of a novel PSMA antibody and its IL-2 conjugate in prostate cancer.

Sugimoto Y, Hirota M, Yoshikawa K, Sumitomo M, Nakamura K, Ueda R, Niwa R, Suzawa T, Yamasaki M, Shitara K, Kato T, Nakamura K.

Anticancer Res. 2014 Jan;34(1):89-97.

PMID:
24403448
8.

Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging.

Dobrenkov K, Olszewska M, Likar Y, Shenker L, Gunset G, Cai S, Pillarsetty N, Hricak H, Sadelain M, Ponomarev V.

J Nucl Med. 2008 Jul;49(7):1162-70. doi: 10.2967/jnumed.107.047324. Epub 2008 Jun 13.

9.

Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.

Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, Albelda SM, June CH.

Cancer Res. 2010 Nov 15;70(22):9053-61. doi: 10.1158/0008-5472.CAN-10-2880. Epub 2010 Oct 5.

10.

Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells.

Chu J, He S, Deng Y, Zhang J, Peng Y, Hughes T, Yi L, Kwon CH, Wang QE, Devine SM, He X, Bai XF, Hofmeister CC, Yu J.

Clin Cancer Res. 2014 Aug 1;20(15):3989-4000. doi: 10.1158/1078-0432.CCR-13-2510. Epub 2014 Mar 27.

11.

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.

Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, Gress RE, Hakim FT, Kochenderfer JN.

Clin Cancer Res. 2013 Apr 15;19(8):2048-60. doi: 10.1158/1078-0432.CCR-12-2422. Epub 2013 Jan 23.

12.

CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.

Song DG, Ye Q, Poussin M, Harms GM, Figini M, Powell DJ Jr.

Blood. 2012 Jan 19;119(3):696-706. doi: 10.1182/blood-2011-03-344275. Epub 2011 Nov 23.

13.

Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.

Hillerdal V, Ramachandran M, Leja J, Essand M.

BMC Cancer. 2014 Jan 18;14:30. doi: 10.1186/1471-2407-14-30.

14.

A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.

Prapa M, Caldrer S, Spano C, Bestagno M, Golinelli G, Grisendi G, Petrachi T, Conte P, Horwitz EM, Campana D, Paolucci P, Dominici M.

Oncotarget. 2015 Sep 22;6(28):24884-94. doi: 10.18632/oncotarget.4670.

15.

Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.

Deng Z, Wu Y, Ma W, Zhang S, Zhang YQ.

BMC Immunol. 2015 Jan 31;16:1. doi: 10.1186/s12865-014-0064-x.

16.

Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.

Friedrich M, Raum T, Lutterbuese R, Voelkel M, Deegen P, Rau D, Kischel R, Hoffmann P, Brandl C, Schuhmacher J, Mueller P, Finnern R, Fuergut M, Zopf D, Slootstra JW, Baeuerle PA, Rattel B, Kufer P.

Mol Cancer Ther. 2012 Dec;11(12):2664-73. doi: 10.1158/1535-7163.MCT-12-0042. Epub 2012 Oct 5.

17.

Treatment of advanced leukemia in mice with mRNA engineered T cells.

Barrett DM, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M, Carroll RG, June CH, Grupp SA.

Hum Gene Ther. 2011 Dec;22(12):1575-86. doi: 10.1089/hum.2011.070. Epub 2011 Sep 23.

18.

Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.

Zhang Q, Wang H, Li H, Xu J, Tian K, Yang J, Lu Z, Zheng J.

Oncotarget. 2017 Feb 7;8(6):9488-9499. doi: 10.18632/oncotarget.14367.

19.

Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease.

Zhang Q, Helfand BT, Carneiro BA, Qin W, Yang XJ, Lee C, Zhang W, Giles FJ, Cristofanilli M, Kuzel TM.

Eur Urol. 2018 May;73(5):648-652. doi: 10.1016/j.eururo.2017.12.008. Epub 2017 Dec 21. Review.

PMID:
29275833
20.

Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.

Shen CJ, Yang YX, Han EQ, Cao N, Wang YF, Wang Y, Zhao YY, Zhao LM, Cui J, Gupta P, Wong AJ, Han SY.

J Hematol Oncol. 2013 May 9;6:33. doi: 10.1186/1756-8722-6-33.

Supplemental Content

Support Center